[CAS NO. 899821-23-9] ACP-105
PRODUCTS SPECIFICATIONS [899821-23-9]
DESCRIPTION [899821-23-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 290.79 |
| Molecular Formula | C16H19ClN2O |
| SMILES | N#CC1=CC=C(N2[C@@H]3C[C@](O)(C)C[C@H]2CC3)C(C)=C1Cl |
4 Publications Citing Use of MCE
Summary
ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC 50 s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively.
IC50 & Target
pEC50: 9.0 (AR wild type), 9.3 (AR T877A mutant) [1] .
In Vitro
ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC 50 s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively. The half-lives of ACP-105 (compound 1) in human hepatocytes is measured and found to be 5.0 h [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ACP-105 enhances freezing in both sham-irradiated and irradiated mice (effect of ACP-105: F=5.44; p=0.028). For MAP-2 immunoreactivity in the cortex of sham-irradiated mice, there is a brain area×ACP-105 interaction (F=6.655; p=0.0027). While ACP-105 reduces MAP-2 immunoreactivity in the sensorymotor cortex, there is a trend towards increased MAP-2 immunoreactivity in the enthorhinal cortex [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 103 mg/mL ( 354.21 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.4389 mL | 17.1945 mL | 34.3891 mL |
| 5 mM | 0.6878 mL | 3.4389 mL | 6.8778 mL |
| 10 mM | 0.3439 mL | 1.7195 mL | 3.4389 mL |
References
- [1] Schlienger N, et al. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem. 2009 Nov 26;52(22):7186-91.
- [2] Dayger C, et al. Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice. Brain Res. 2011 Mar 24;1381:134-40.